New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
11:29 EDTRPRX, UTHR, GME, RHT, TIBXOptions with decreasing implied volatility: RPRX UTHR GME RHT TIBX
News For RPRX;UTHR;GME;RHT;TIBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTTIBXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:52 EDTTIBXTIBCO reinstated with a Hold at Deutsche Bank
Subscribe for More Information
06:02 EDTGMEStocks with implied volatility above IV index mean; GME GMCR
Subscribe for More Information
October 29, 2014
09:51 EDTRPRXRepros Therapeutics to host investor and analyst day
Investor and Analyst Day to be held in New York on October 31 at 7:30 am.
07:14 EDTTIBXTIBCO, Ericsson form global OSS/BSS partnership
Subscribe for More Information
06:06 EDTGMEGameStop implied volatility of 52 at upper end of index mean range
October 28, 2014
11:44 EDTGMEGameStop weakness on Wal-Mart news a buying opportunity, says Piper Jaffray
Piper Jaffray believes the impact of Wal-Mart (WMT) on GameStop's (GME) used business will be immaterial and views today's pullback as a buying opportunity. Piper notes that the entrance of Wal-Mart into any market should not be taken lightly, but other retailers have tried and failed before to enter the used game business and that Wal-Mart's entry actually refutes the bear thesis on GameStop that the used game business is not attractive. The firm maintains its Overweight rating and $53 price target on GameStop.
10:27 EDTGMEGameStop retreats after Wal-Mart begins selling used video games
Subscribe for More Information
09:08 EDTGMEWal-Mart says 1,700 stores selling pre-owned video games
Subscribe for More Information
06:11 EDTUTHRUnited Therapeutics reports Q3 adjusted EPS $3.91
May not compare to consensus $1.97. Reports Q3 revenue $329.95M, consensus $335.08M. Reports Q3 EPS (53c).
October 24, 2014
12:30 EDTGMEGameStop November calls active
Subscribe for More Information
October 23, 2014
14:00 EDTRPRXRepros Therapeutics volatility elevated as shares trade near two-year low
Repros Therapeutics overall option implied volatility of 158 is above its 26-week average of 93 according to Track Data, suggesting large price movement.
October 21, 2014
18:36 EDTRPRXOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTRPRXRepros Therapeutics: Results from Androxal study exhibit positive safety profile
Repros Therapeutics reported results from a large, controlled, long-term safety study comparing Androxal to a placebo. In this study of Androxal, ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. The last patient completed this study in late September. The Company's planned NDA will include study ZA-303, which will provide a significant portion of the support of long-term safety by providing data from 141 subjects exposed for one year or more. Over 200 subjects reached this milestone in the entire exposure database. ICH guidance for drugs to treat non-life-threatening conditions suggests that a minimum of 100 subjects should be exposed to the drug for one year.
08:05 EDTTIBXTIBCO Software chosen by Rail Europe 4A
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use